Omega 3 Fatty Acids reduces Breast Cancer Relapse. But that finding is only part of the story. Based on the thorough, well-studied, well-researched article linked and excerpted below by Medscape, Omega-3 EPA/DHAreduces Breast Cancer Relapse by 25%! Also, Omega-3 EPA/DHA supplementation:
- Reduces cardiac events
- Reduces bone loss and joint pain (Arthralgias)
- Reduces insulin resistance and muscle loss/weight gain
- Reduces chemobrain by 40-50%
As a long-term cancer survivor myself who is often amazed by articles citing medical breakthroughs of toxic, side-effect inducing chemotherapy. Breakthroughs that offer additional months of survival or minor improvements over the standard-of-care metrics. The key issue below is that Omega-3 EPA/DHA supplementation prevents breast cancer relapse and heals side effects more that ANY conventional therapy can. And yes, the benefits of Omega-3 EPA/DHA is evidence-based. Virtually medical fact.
I take Life Extension Super Omega-3 EPA/DHA as this brand has been tested and approved for purity and freshness by ConsumerLab.com, an independent testing agency. The combination of fish oil, olive extract and sesame lignin extract offers the best formula of omega 3 DHA/EPA.
For more information about anti-oxidant supplementation to reduce the risk of breast cancer or breast cancer relapse, scroll down the page, post a question and I will reply ASAP.
Survivor, Creator, Director PeopleBeatingCancer
Omega-3 Fatty Acids and Breast Cancer Survivorship
There is also interest in EPA and DHA for improvement of outcomes after a diagnosis of breast cancer. Breast cancer recurrence, cardiovascular events, weight gain and obesity, bone density loss, and chemotherapy-associated cognitive impairment and peripheral neuropathy are common concerns during the survivorship period. Although there is little in the way of definitive interventional trials, we will review here some of the more interesting preliminary results…
EPA and DHA and Reduction of Breast Cancer Recurrence
Higher intakes of EPA and DHA from dietary sources were reported to be associated with a 25% reduction in breast cancer recurrence and improved overall mortality in a large cohort of over 3,000 women with early stage breast cancer followed for a median of 7 years.
EPA and DHA to Reduce Cardiac Events
Cardiac events are the second most common cause of mortality in women with breast cancer, and the most common cause of death for women with stage I breast cancer over the age of 65. EPA and DHA reduce triglycerides and platelet aggregation and are thought to have an anti-arrhythmic effect. EPA and DHA supplementation have been noted to be associated with reduced cardiac deaths in the general population.[75,76]…
EPA and DHA to Reduce Bone Density Loss and Arthralgias
Loss of bone density and increased fracture rate are a side effect of premature menopause caused by cytotoxic chemotherapy or surgical ovarian ablation in premenopausal women or use of aromatase inhibitors in postmenopausal women. EPA and DHA probably inhibit RANK ligand and osteoclast formation. A small randomized pilot trial suggests that 3 g/day EPA and DHA inhibits bone reabsorption in individuals taking aromatase inhibitors. The anti-inflammatory activity and beneficial effects of EPA and DHA on rheumatoid arthritis have led to a clinical trial of high-dose EPA and DHA versus placebo in women who have aromatase inhibitor-induced arthralgias. This cooperative group study of 262 women has been reported in abstract form and no benefit was observed. A small randomized trial of omega-3 fatty acids to protect against taxane-induced neuropathy suggests benefitand further studies are needed…
EPA and DHA to Prevent Insulin Resistance and Sarcopenic Weight Gain
EPA and DHA help prevent obesity and insulin resistance particularly in animal models fed a high-fat diet,[85,86] but effects in humans have yet to be proven. Sarcopenic weight gain is common during adjuvant chemotherapy for breast cancer. The anabolic effects of EPA and DHA might help reduce muscle mass loss and weight gain during treatment and weight gain following diagnosis, but studies in this area have yet to be conducted.[87,88] Results of the Muscle Mass, Omega-3, Diet, Exercise and Lifestyle (MODEL) trial in healthy individuals aged >70 years examining the effects of 90 minutes of exercise weekly, vitamin D3 (2,000 IU/day) or 1 g EPA and DHA daily are awaited with interest...
EPA and DHA and Cognition
Cognitive abnormalities (chemobrain) are observed in 20 to 70% of women after chemotherapy depending on the agents used, intensity and duration of treatment, predisposing factors, and type and scoring of cognitive tests.[90,91] DHA is the most abundant PUFA in the brain and is involved in multiple functions including cell signaling, neurogenesis, neuroprotection, and learning and memory. A number of epidemiologic studies show a 40 to 50% reduction in risk of multicause dementia with increased dietary intake of DHA or increased blood levels of DHA. In meta-analyses, DHA supplementation improves attention, processing speed and immediate recall, learning, and memory in individuals with cognitive impairment without dementia but not in those with dementia.[92,93] ”